These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 17169035)

  • 1. Detection of a proteasome in Pneumocystis carinii and its modulation by specific proteasome inhibitors.
    Tronconi E; Mazza F; Valerio A; Rinaudo MT; Piccinini M; Anselmino A; Cargnel A; Atzori C
    J Eukaryot Microbiol; 2006; 53 Suppl 1():S142-3. PubMed ID: 17169035
    [No Abstract]   [Full Text] [Related]  

  • 2. The non-peptidic HIV protease inhibitor tipranavir and two synthetic peptidomimetics (TS98 and TS102) modulate Pneumocystis carinii growth and proteasome activity of HEL299 cell line.
    Mazza F; Tronconi E; Valerio A; Groettrup M; Kremer M; Tossi A; Benedetti F; Cargnel A; Atzori C
    J Eukaryot Microbiol; 2006; 53 Suppl 1():S144-6. PubMed ID: 17169036
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of proteasome inhibitors with different chemical structures on the ubiquitin-proteasome system in vitro.
    Csizmadia V; Csizmadia E; Silverman L; Simpson C; Raczynski A; O'Brien L; Gallacher M; Cardoza K; Kadambi VJ; Fedyk ER; Alden CL
    Vet Pathol; 2010 Mar; 47(2):358-67. PubMed ID: 20124009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel proteasome inhibitors to overcome bortezomib resistance.
    Ruschak AM; Slassi M; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the proteasome pathway.
    Tsukamoto S; Yokosawa H
    Expert Opin Ther Targets; 2009 May; 13(5):605-21. PubMed ID: 19397479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Semi-high throughput method of measuring proteasome inhibition in vitro and in cultured cells.
    Keyomarsi K; Efuet ET; Bui TN
    Cell Biol Toxicol; 2011 Apr; 27(2):123-31. PubMed ID: 20853140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132.
    Crawford LJ; Walker B; Ovaa H; Chauhan D; Anderson KC; Morris TC; Irvine AE
    Cancer Res; 2006 Jun; 66(12):6379-86. PubMed ID: 16778216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selectively killing transformed cells through proteasome inhibition.
    Grant S
    Cell Cycle; 2009 Oct; 8(19):3074-5. PubMed ID: 19770579
    [No Abstract]   [Full Text] [Related]  

  • 9. Proteasome inhibition: mechanism of action.
    DeMartino GN
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S5-9. PubMed ID: 19791423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit.
    Blackburn C; Gigstad KM; Hales P; Garcia K; Jones M; Bruzzese FJ; Barrett C; Liu JX; Soucy TA; Sappal DS; Bump N; Olhava EJ; Fleming P; Dick LR; Tsu C; Sintchak MD; Blank JL
    Biochem J; 2010 Sep; 430(3):461-76. PubMed ID: 20632995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib.
    Berkers CR; Leestemaker Y; Schuurman KG; Ruggeri B; Jones-Bolin S; Williams M; Ovaa H
    Mol Pharm; 2012 May; 9(5):1126-35. PubMed ID: 22432738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The proteasome as a target for prevention of restenosis following vascular injury.
    Ayub B; Mangalmurti S; Matsumura ME
    Vasa; 2011 Nov; 40(6):425-6. PubMed ID: 22191123
    [No Abstract]   [Full Text] [Related]  

  • 13. Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib.
    Berkers CR; Verdoes M; Lichtman E; Fiebiger E; Kessler BM; Anderson KC; Ploegh HL; Ovaa H; Galardy PJ
    Nat Methods; 2005 May; 2(5):357-62. PubMed ID: 15846363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.
    Mitsiades CS
    J Clin Oncol; 2015 Mar; 33(7):782-5. PubMed ID: 25605842
    [No Abstract]   [Full Text] [Related]  

  • 15. Proteasomal chymotrypsin-like peptidase activity is required for essential functions of human monocyte-derived dendritic cells.
    Naujokat C; Berges C; Höh A; Wieczorek H; Fuchs D; Ovens J; Miltz M; Sadeghi M; Opelz G; Daniel V
    Immunology; 2007 Jan; 120(1):120-32. PubMed ID: 17083604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma.
    Gutman D; Morales AA; Boise LH
    Leukemia; 2009 Nov; 23(11):2181-3. PubMed ID: 19516276
    [No Abstract]   [Full Text] [Related]  

  • 17. Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib.
    Subklewe M; Sebelin-Wulf K; Beier C; Lietz A; Mathas S; Dörken B; Pezzutto A
    Hum Immunol; 2007 Mar; 68(3):147-55. PubMed ID: 17349869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.
    Sutheesophon K; Kobayashi Y; Takatoku MA; Ozawa K; Kano Y; Ishii H; Furukawa Y
    Acta Haematol; 2006; 115(1-2):78-90. PubMed ID: 16424655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors.
    Zhu H; Zhang L; Dong F; Guo W; Wu S; Teraishi F; Davis JJ; Chiao PJ; Fang B
    Oncogene; 2005 Jul; 24(31):4993-9. PubMed ID: 15824729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage therapy for refractory rejection and persistence of donor-specific antibodies after intestinal transplantation using the proteasome inhibitor bortezomib.
    Gerlach UA; Schoenemann C; Lachmann N; Koch M; Pascher A
    Transpl Int; 2011 May; 24(5):e43-5. PubMed ID: 21155900
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.